Drugs Losing Exclusivity in 2026 & Key Intermediates
1 drugs expire in 2026 (public sources), 1 with recorded synthesis routes; key intermediates of 1 drugs are already available through the Unibest supply network. Generic developers typically secure intermediate supply 2–3 years ahead — use this table for shortlisting and RFQ.
| Drug | Tier | Expiry | Indications | Routes | CAS count | Available |
|---|---|---|---|---|---|---|
| 利伐沙班 Rivaroxaban | A · Act now | 2026 | 肺栓塞、中风、先天性心脏缺损 | 6 | 46 | Available ×46 |
Frequently asked questions
Which drugs lose exclusivity in 2026?
1 drugs expire in 2026 per public sources: Rivaroxaban.
When should we start sourcing intermediates for 2026 launches?
Generic developers typically secure development-scale supply 2–3 years before expiry. 1 of the 1 drugs in this table already have on-sale intermediates in the Unibest network; the rest can be RFQ'd per CAS.
Are route and CAS data verified?
All fields are structured data cross-verified from public sources; intermediates carry registry codes and CAS numbers, and every "Available" badge links to real listings.
Source: cross-verified structured fields · Expiry years are public-source estimates; consult individual agencies for authoritative dates · 2026-09-24